OR WAIT null SECS
June 06, 2024
An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.
June 05, 2024
The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.
The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.
June 04, 2024
The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.
A retrospective study explores the connection between adherence and racial/ethnic disparities among patients with Alzheimer’s disease, along with similar dementias.
June 03, 2024
The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies.
In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora offers his thoughts on Cencora's inaugural ThinkLive Cell and Gene Therapy Summit.
May 31, 2024
Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.
May 30, 2024
These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.
According to the IATA, the streak continues—April represents the fifth consecutive month of positive development.